 | Here’s What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
finance.yahoo.com - June 20 at 12:21 AM |
 | Madrigal Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:MDGL)
www.americanbankingnews.com - June 13 at 6:13 AM |
| Investors Purchase High Volume of Madrigal Pharmaceuticals Call Options (NASDAQ:MDGL)
www.americanbankingnews.com - June 13 at 6:13 AM |
| Madrigal Pharmaceuticals Inc Expected to Post Q2 2019 Earnings of ($1.03) Per Share (NASDAQ:MDGL)
www.americanbankingnews.com - June 12 at 6:59 AM |
| Madrigal Pharmaceuticals (NASDAQ:MDGL) Rating Increased to Buy at B. Riley
www.americanbankingnews.com - June 10 at 8:12 AM |
| Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
finance.yahoo.com - June 4 at 8:51 AM |
| -$1.03 EPS Expected for Madrigal Pharmaceuticals Inc (MDGL) This Quarter
www.americanbankingnews.com - June 1 at 6:12 PM |
| Madrigal Pharmaceuticals Inc (MDGL) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 29 at 2:36 AM |
 | Madrigal, Galmed, And Galectin In Phase 3 NASH: The Need For Therapeutic Diversity
seekingalpha.com - May 22 at 6:59 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
finance.yahoo.com - May 15 at 8:06 PM |
| If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
finance.yahoo.com - May 8 at 7:18 PM |
| If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today
finance.yahoo.com - May 8 at 7:18 PM |
| Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
finance.yahoo.com - May 8 at 8:47 AM |
| Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy?
finance.yahoo.com - May 1 at 7:09 PM |
 | Madrigal Pharmaceuticals Enters Oversold Territory (MDGL)
www.nasdaq.com - April 22 at 5:59 PM |
| Madrigal's MGL-3196: Not Ideal, But Currently The Best
seekingalpha.com - April 17 at 7:04 PM |
| MGL-3196: Not Ideal, But Currently The Best
seekingalpha.com - April 16 at 7:21 PM |
| Madrigal And Resmetirom In NASH: Killing Liver Fat
seekingalpha.com - April 16 at 7:21 PM |
| Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
finance.yahoo.com - April 8 at 8:53 AM |
| Madrigal Pharma launches late-stage study of MGL-3196 in NASH
seekingalpha.com - March 28 at 9:00 AM |
| Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
finance.yahoo.com - March 28 at 9:00 AM |
 | Madrigal Pharmaceuticals Inc
www.bloomberg.com - March 19 at 9:06 AM |
 | Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights - GlobeNewswire
globenewswire.com - March 1 at 9:20 AM |
| Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 27 at 8:46 AM |
| MDGL: Insiders vs. Shorts
www.nasdaq.com - February 19 at 6:40 PM |
| Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
finance.yahoo.com - February 17 at 6:46 PM |
| Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
finance.yahoo.com - February 12 at 6:20 PM |
| Viking Therapeutics, Madrigal move up as Gilead liver drug fails to meet goals
seekingalpha.com - February 11 at 6:19 PM |
| Viking Therapeutics: Anatomy Of A Multi-Bagger
seekingalpha.com - January 15 at 5:51 PM |
| Here's Why Viking Therapeutics Slid 32.2% in December
finance.yahoo.com - January 11 at 6:19 PM |
| Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018
finance.yahoo.com - January 8 at 6:00 PM |
| Goldman Called 2019 ‘The Year of NASH,’ Others Say Not So Fast - Bloomberg
www.bloomberg.com - December 19 at 8:48 AM |
| Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
finance.yahoo.com - December 13 at 10:13 AM |
| 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
finance.yahoo.com - December 12 at 8:45 AM |
| Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
finance.yahoo.com - December 8 at 4:58 PM |
| Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of Shares
finance.yahoo.com - November 24 at 8:33 AM |
 | Pre-Open Movers 11/19: (AKER) (ZAYO) (REN) Higher; (SPB) (XEC) (MDGL) Lower (more...)
www.streetinsider.com - November 19 at 5:01 PM |
 | Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
www.benzinga.com - November 19 at 5:01 PM |
| US STOCKS ON THE MOVE-Nvidia, Nordstrom, PG&E Corp, Facebook
www.nasdaq.com - November 16 at 5:33 PM |
| US STOCKS ON THE MOVE-PG&E, Chipmakers, Nordstrom, Facebook, Williams-Sonoma
www.nasdaq.com - November 16 at 5:33 PM |
| It's Going to Be a Big Year for These Pharma Companies
www.bloomberg.com - November 14 at 5:04 PM |
| Imprimis Pharmaceuticals and Eyenovia among healthcare gainers; Madrigal Pharmaceuticals leads the losers
seekingalpha.com - November 14 at 5:04 PM |
| Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.
finance.yahoo.com - November 14 at 5:04 PM |
| Madrigal (MDGL) Says Phase 2 Results for its MGL-3196 in NASH Presented during Presidential Plenary Clinical Session of The Liver Meeting
www.streetinsider.com - November 13 at 8:32 AM |
| Phase 2 Results for Madrigal's MGL-3196 in...
www.benzinga.com - November 12 at 4:56 PM |
| Madrigal Pharma up 3% on positive mid-stage MGL-3196 data
seekingalpha.com - November 12 at 4:56 PM |
| Why Madrigal Pharmaceuticals Stock Slumped in October
finance.yahoo.com - November 12 at 4:56 PM |
| Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
finance.yahoo.com - November 12 at 4:56 PM |
| Madrigal preparing for late-stage testing of experimental NASH treatment
finance.yahoo.com - November 12 at 4:56 PM |
| Madrigal Pharmaceuticals misses by $0.03
seekingalpha.com - November 6 at 8:41 AM |
